Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Fish and Richardson
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Medtronic
Cerilliant
Baxter
Citi
Cipla

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,623,868

« Back to Dashboard

Which drugs does patent 8,623,868 protect, and when does it expire?

Patent 8,623,868 protects TEMODAR and is included in one NDA.

This patent has thirty-two patent family members in twenty-three countries.
Summary for Patent: 8,623,868
Title:Processes of making and using pharmaceutical formulations of antineoplastic agents
Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
Inventor(s): Ugwu; Sydney (Gurnee, IL), Radhakrishnan; Vinay (Thousand Oaks, CA), Ihnat; Peter M. (Brooklyn, NY), Witchey-Lakshmanan; Lenore C. (Piscataway, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/290,251
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,623,868

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme TEMODAR temozolomide POWDER;INTRAVENOUS 022277-001 Feb 27, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,623,868

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,987,108 Pharmaceutical formulations of antineoplastic agents and processes of making and using the same ➤ Try a Free Trial
8,076,335 Processes of making pharmaceutical formulations of antineoplastic agents ➤ Try a Free Trial
7,674,790 Processes of making and using pharmaceutical formulations of antineoplastic agents ➤ Try a Free Trial
7,786,118 Pharmaceutical formulations of antineoplastic agents ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,623,868

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1478339 ➤ Try a Free Trial
Singapore 161101 ➤ Try a Free Trial
Portugal 1478339 ➤ Try a Free Trial
Poland 205936 ➤ Try a Free Trial
Poland 372319 ➤ Try a Free Trial
New Zealand 534378 ➤ Try a Free Trial
Norway 335045 ➤ Try a Free Trial
Norway 20043961 ➤ Try a Free Trial
Mexico PA04008133 ➤ Try a Free Trial
South Korea 100970528 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Argus Health
US Army
Johnson and Johnson
Accenture
UBS
Daiichi Sankyo
Julphar
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot